Antineoplastic Agents: Cytotoxic Agents: Alkylating Agents
IDACA1 “Dacarbazine injection” 200 mg/vial
適應症：惡性黑色素腫瘤症狀之改善。
Usual dose:
Metastatic melanoma: IV
Adult: 2-4.5 mg/kg daily for 10 days, repeat at 4-wk intervals or 200-250 mg/m2 BSA daily for 5 days, repeat at 3-wk intervals or 850 mg/m2 BSA by infusion, repeat at 3-wk intervals.
Hodgkin’s disease:
Adult: 150 mg/m2 BSA daily for 5 days, repeat q4w or 375 mg/m2 BSA every 15 days in combination with other agents.
Soft tissue sarcoma:
Adult: 250 mg/m2 BSA daily for 5 days repeated every 3 wk. Usually given with doxorubicin.
Incompatibility: Incompatible with hydrocortisone sodium succinate, L-cysteine, sodium hydrogen carbonate and concentrated heparin (25 mg/ml).
Adverse effect:
Leucopenia, thrombocytopenia, anorexia, nausea, diarrhoea, vomiting; flu-like syndrome, myalgia, malaise, facial flushing, paraesthesia, skin reactions, rashes; alopoecia, photosensitivity reactions.Potentially Fatal: Myelosuppression; hepatotoxicity, anaphylaxis.